| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $84,427 | 13 | 100 |
Sells | $0 | 0 | 0 |
| Agah Ramtin | Chief Medical Officer | 7 | $55,968 | 0 | $0 | $55,968 |
| VOLL MARK | Chief Financial Officer | 2 | $19,690 | 0 | $0 | $19,690 |
| Bagai Shaun | Chief Executive Officer | 3 | $8,769 | 0 | $0 | $8,769 |
| Marton Laurence | director | 1 | $0 | 0 | $0 | $0 |
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Over the last 12 months, insiders at RenovoRx, Inc. have bought $84,427 and sold $0 worth of RenovoRx, Inc. stock.
On average, over the past 5 years, insiders at RenovoRx, Inc. have bought $94,987 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Agah Ramtin (Chief Medical Officer) — $55,968. VOLL MARK (Chief Financial Officer) — $19,690. Bagai Shaun (Chief Executive Officer) — $8,769.
The last purchase of 25,000 shares for transaction amount of $19,690 was made by VOLL MARK (Chief Financial Officer) on 2026‑05‑19.
| 2026-05-19 | VOLL MARK | Chief Financial Officer | 25,000 0.0656% | $0.79 | $19,690 | +42.70% | ||
| 2026-03-20 | Bagai Shaun | Chief Executive Officer | 24,300 – | $0 | $0 | 0.00% | ||
| 2026-03-20 | VOLL MARK | Chief Financial Officer | 97,200 – | $0 | $0 | 0.00% | ||
| 2026-03-20 | Marton Laurence | director | 9,720 – | $0 | $0 | 0.00% | ||
| 2026-01-21 | Agah Ramtin | Chief Medical Officer | 10,000 0.0273% | $1.00 | $9,975 | -2.61% | ||
| 2025-12-31 | Agah Ramtin | Chief Medical Officer | 9,795 0.0263% | $0.86 | $8,424 | +16.65% | ||
| 2025-12-30 | Agah Ramtin | Chief Medical Officer | 205 0.0005% | $0.83 | $169 | +11.96% | ||
| 2025-12-18 | Bagai Shaun | Chief Executive Officer | 5,000 0.0137% | $0.90 | $4,507 | +8.12% | ||
| 2025-12-17 | Bagai Shaun | Chief Executive Officer | 5,000 0.0134% | $0.85 | $4,262 | +11.67% | ||
| 2025-12-16 | Agah Ramtin | Chief Medical Officer | 12,000 0.033% | $0.85 | $10,200 | +15.11% | ||
| 2025-12-05 | Agah Ramtin | Chief Medical Officer | 10,000 0.0278% | $0.96 | $9,600 | +3.05% | ||
| 2025-11-24 | Agah Ramtin | Chief Medical Officer | 12,000 0.0329% | $0.80 | $9,600 | +22.75% | ||
| 2025-11-21 | Agah Ramtin | Chief Medical Officer | 10,000 0.0274% | $0.80 | $8,000 | +21.18% | ||
| 2025-08-25 | Bagai Shaun | Chief Executive Officer | 5,000 0.0132% | $0.91 | $4,549 | +6.86% | ||
| 2025-08-22 | Bagai Shaun | Chief Executive Officer | 5,000 0.0138% | $0.95 | $4,748 | +2.00% | ||
| 2025-06-05 | Agah Ramtin | Chief Medical Officer | 21,000 0.0574% | $1.40 | $29,400 | -28.57% | ||
| 2025-04-15 | Agah Ramtin | Chief Medical Officer | 15,000 0.0468% | $0.90 | $13,500 | +15.56% | ||
| 2025-04-15 | Bagai Shaun | Chief Executive Officer | 7,500 0.0236% | $0.91 | $6,821 | +15.56% | ||
| 2025-04-11 | Agah Ramtin | Chief Medical Officer | 20,000 0.0554% | $0.80 | $16,000 | +34.72% | ||
| 2025-04-10 | Kocak Ron | VP Controller and PAO | 6,500 0.0178% | $0.79 | $5,135 | +31.48% |
| Agah Ramtin | Chief Medical Officer | 798460 1.7693% | $1.03M | 14 | 0 | +14.64% |
| Bagai Shaun | Chief Executive Officer | 313357 0.6944% | $404,230.53 | 10 | 0 | +16.21% |
| VOLL MARK | Chief Financial Officer | 142380 0.3155% | $183,670.20 | 2 | 0 | |
| Marton Laurence | director | 9720 0.0215% | $12,538.80 | 3 | 0 | +22.62% |
| Spiegel Robert J. | director | 40983 0.0908% | $52,868.07 | 1 | 0 | +15.24% |
| Macfarlane K. Angela | director | 40983 0.0908% | $52,868.07 | 1 | 0 | +15.24% |
| Kocak Ron | VP Controller and PAO | 12595 0.0279% | $16,247.55 | 3 | 0 | +28.93% |
| Nelms Angela | Chief Operating Officer | 1100 0.0024% | $1,419.00 | 1 | 0 | +10.48% |
$5,831,763 | 118 | -33.78% | $66.68M | |
$17,525,882 | 60 | 5.22% | $64.7M | |
$103,288,323 | 51 | 4.78% | $56.52M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$24,478,755 | 37 | -34.59% | $53.59M |
| Increased Positions | 16 | +44.44% | 777,021 | +10.9% |
| Decreased Positions | 13 | -36.11% | 1M | -18.67% |
| New Positions | 8 | New | 471,855 | New |
| Sold Out Positions | 6 | Sold Out | 1M | Sold Out |
| Total Postitions | 39 | +8.33% | 7M | -7.77% |
| Aigh Capital Management Llc | $2,184.00 | 7.07% | 2.62M | -852,082 | -24.57% | 2025-09-30 |
| Vanguard Group Inc | $1,340.00 | 4.34% | 1.61M | -58,479 | -3.52% | 2025-09-30 |
| Awm Investment Company, Inc. | $721.00 | 2.34% | 863,790 | -1M | -53.81% | 2025-09-30 |
| Bleichroeder Lp | $450.00 | 1.46% | 538,621 | +38,621 | +7.72% | 2025-09-30 |
| Geode Capital Management, Llc | $310.00 | 1% | 371,484 | +17,881 | +5.06% | 2025-09-30 |
| Renaissance Technologies Llc | $262.00 | 0.85% | 313,550 | +61,750 | +24.52% | 2025-09-30 |
| Citadel Advisors Llc | $101.00 | 0.33% | 121,341 | +121,341 | New | 2025-09-30 |
| Nixon Peabody Trust Co | $81.00 | 0.26% | 97,165 | 0 | 0% | 2025-09-30 |
| Corsair Capital Management, L.P. | $78.00 | 0.25% | 93,473 | -1,900 | -1.99% | 2025-09-30 |
| Chicago Partners Investment Group Llc | $77.00 | 0.25% | 92,356 | 0 | 0% | 2025-09-30 |